FPH provides first half FY27 guidance, updates FY27 outlook
Fisher & Paykel Healthcare (FPH) provided first-half FY27 guidance, expecting $1.24B revenue and $280M net profit, up 14% and 24% respectively. Full-year outlook raised to $2.47B-$2.57B revenue and $525M-$565M net profit, including $23M in tariff refunds. Growth driven by strong demand and clinical practice changes.
How this was made
The 30-second read
Why it matters
Guidance suggests a stronger operating environment and could lift the stock.
Market read
First‑hand guidance update provides fresh material for traders.
What to watch
Potential currency fluctuations and regulatory changes could affect actual results.
Background
Fisher & Paykel Healthcare is a New Zealand‑based manufacturer of respiratory‑care devices.
Ticker impact
Fisher & Paykel Healthcare released FY27 first‑half and full‑year revenue and profit guidance, updating its outlook.
Potential upside as investors price in higher earnings outlook.
Guidance numbers are materially above prior guidance and reflect a 14% revenue growth and 24% profit growth YoY.
Market effects
Positive signal for the medical‑device and respiratory‑care sector.
Supports New Zealand‑listed health‑care stocks.
May influence global investors tracking healthcare earnings trends.
Counterpoint
If margin improvements stall, the guidance could be overly optimistic.
Key entities
- ExecutiveLewis Gradon
Managing Director and CEO of Fisher & Paykel Healthcare.



